Clinical Study Results

Most common adverse reactions during the study

Anifrolumab Placebo

(Out of 180 participants) (Out of 182 participants)

Infection of the upper airways

8.3% (15) 2.7% (5)

of the nose and throat

Nose and throat infection 6.7% (12) 2.2% (4)

Shingles 6.1% (11) 0.0% (0)

Infection of the main airways

3.9% (7) 1.1% (2)

of the lungs

Urinary tract infection 3.3% (6) 3.8% (7)

Pneumonia 2.8% (5) 3.8% (7)

Sinus infection 1.1% (2) 2.2% (4)

Cold sore 1.1% (2) 1.6% (3)

Infection of the gut 0.6% (1) 1.6% (3)

How has this study helped patients and researchers?

This study helped researchers learn more about using anifrolumab in participants with lupus.

Researchers look at the results of many studies to decide which treatments work best and are safest. This summary shows only the main results from this one study. Other studies may provide new information or different results.

Further clinical studies with anifrolumab are planned.